Differential endocytosis of tissue plasminogen activator by serpins PAI-1 and PAI-2 on human peripheral blood monocytes

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Thrombosis and Haemostasis

• Publication date

  2010-09-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1160/TH10-02-0121PMID 20838737
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity

  2009cited by this paper
• Tissue-Type Plasminogen Activator Is a Regulator of Monocyte Diapedesis through the Brain Endothelial Barrier

  2008cited by this paper
• Plasminogen activator inhibitor type 2 inhibits cell surface associated tissue plasminogen activator in vitro

  2008cited by this paper
• Tissue-Type Plasminogen Activator Is a Regulator of Monocyte Diapedesis through the Brain Endothelial Barrier1

  2008cited by this paper
• Tissue-type plasminogen activator promotes murine myofibroblast activation through LDL receptor-related protein 1-mediated integrin signaling.

  2007influential reference
• A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells.

  2007cited by this paper
• Endocytic receptor LRP together with tPA and PAI‐1 coordinates Mac‐1‐dependent macrophage migration

  2006cited by this paper
• Stage specific gene expression of serpins and their cognate proteases during myeloid differentiation

  2006cited by this paper
• Plasminogen activators and their inhibitors in human saliva and salivary gland tissue.

  2006cited by this paper
• The Urokinase/PAI-2 Complex

  2006cited by this paper
• Binding areas of urokinase‐type plasminogen activator–plasminogen activator inhibitor‐1 complex for endocytosis receptors of the low‐density lipoprotein receptor family, determined by site‐directed mutagenesis

  2006cited by this paper
• Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages.

  2004cited by this paper
• Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo.

  2004cited by this paper
• Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein.

  2003cited by this paper
• The Plasminogen Activating System in Periodontal Health and Disease

  2002cited by this paper
• Diverse roles for the LDL receptor family.

  2002cited by this paper
• The Serpins Are an Expanding Superfamily of Structurally Similar but Functionally Diverse Proteins

  2001cited by this paper
• Interaction between the P14 Residue and Strand 2 of β-Sheet B Is Critical for Reactive Center Loop Insertion in Plasminogen Activator Inhibitor-2*

  2001cited by this paper
• Cellular Degradation of Free and Inhibitor-bound Tissue-type Plasminogen Activator

  2000cited by this paper
• Monocyte Plasminogen Activator Inhibitor 2 (PAI-2) Inhibits u-PA-mediated Fibrin Clot Lysis and Is Cross-linked to Fibrin

  1999cited by this paper
• Differential expression of plasminogen activators and their inhibitors in an organotypic skin coculture system

  1999cited by this paper
• Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins.

  1998cited by this paper
• Plasminogen Activator Inhibitor 1 Contains a Cryptic High Affinity Receptor Binding Site that Is Exposed upon Complex Formation with Tissue-type Plasminogen Activator ,

  1998cited by this paper
• Significance of the Plasminogen Activator Inhibitor of Placental Type (PAI-2) In Pregnancy

  1998cited by this paper
• Plasminogen activator in acute myeloid leukaemic marrows: u‐PA in contrast to t‐PA in normal marrow

  1998cited by this paper
• Plasminogen Activator Inhibitor-1 Contains a Cryptic High Affinity Binding Site for the Low Density Lipoprotein Receptor-related Protein*

  1998cited by this paper
• The p11 subunit of the annexin II tetramer plays a key role in the stimulation of t-PA-dependent plasminogen activation.

  1998cited by this paper
• The interaction of recombinant tissue type plasminogen activator and recombinant plasminogen activator (r-PA/BM 06.022) with human endothelial cells.

  1997cited by this paper
• Molecular characterization of plasminogen activators in human gingival crevicular fluid.

  1995cited by this paper
• Thrombin modulates synthesis of plasminogen activator inhibitor type 2 by human peripheral blood monocytes.

  1995cited by this paper
• Cathepsin D-like aspartyl protease activity mediates the degradation of tissue-type plasminogen activator/plasminogen activator inhibitor-1 complexes in human monocytes.

  1995cited by this paper
• Biological and clinical aspects of plasminogen activator inhibitor type 2.

  1995cited by this paper
• Degradation of tissue-type plasminogen activator by human monocyte-derived macrophages is mediated by the mannose receptor and by the low-density lipoprotein receptor-related protein.

  1995influential reference
• The role of plasminogen activator inhibitor type 1 in the clearance of tissue-type plasminogen activator by rat hepatoma cells.

  1994cited by this paper
• Differential expression of plasminogen activators and their inhibitors in an organotypic skin coculture system.

  1993cited by this paper
• Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor.

  1993cited by this paper
• Demonstration of a specific clearance receptor for tissue-type plasminogen activator on rat Novikoff hepatoma cells.

  1992cited by this paper
• Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system.

  1991cited by this paper
• Binding of tissue plasminogen activator to human monocytes and monocytoid cells.

  1991cited by this paper
• Binding of tissue-type plasminogen activator by the mannose receptor.

  1991influential reference
• Plasminogen activator inhibitor 2 (PAI-2) is not inactivated by exposure to oxidants which can be released from activated neutrophils.

  1990cited by this paper
• Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia.

  1989cited by this paper
• Human monocytes can produce tissue-type plasminogen activator

  1989cited by this paper
• Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.

  1988cited by this paper
• Characterization of the interaction in vivo of tissue-type plasminogen activator with liver cells.

  1988cited by this paper
• Plasminogen Activator Inhibitor-1 Is the Primary Inhibitor of Tissue-Type Plasminogen Activator in Pregnancy Plasma

  1987cited by this paper
• Immunological characterisation of plasminogen activators in the human vessel wall.

  1983cited by this paper
• Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.

  1982cited by this paper
• Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture.

  1981cited by this paper

• Plasminogen Activator Inhibitor-1 is internalized by endothelial cells via macropinocytosis to evade degradation

  2024cites this paper
• A Novel Role for Plasminogen Activator Inhibitor Type-2 as a Hypochlorite-Resistant Serine Protease Inhibitor and Holdase Chaperone

  2022cites this paper
• Characterisation of SerpinB2 as a stress response modulator

  2015cites this paper
• Is plasminogen activator inhibitor type 2 really a plasminogen activator inhibitor after all?

  2014cites this paper
• Plasminogen Activator Inhibitor-2 Polymorphism Associates with Recurrent Coronary Event Risk in Patients with High HDL and C-Reactive Protein Levels

  2013cites this paper
• Development of targeted anticancer agents using novel N-alkylisatin derivatives

  2012cites this paper
• Prediction of thrombus resolution after intravenous thrombolysis assessed by CT-based thrombus imaging

  2012cites this paper
• Understanding the role of plasminogen activator inhibitor type-2 (PAI-2, SerpinB2) in cancer: the relationship between biochemical properties and cellular function

  2011cites this paper
• Monocytes: Possible mediators of benefits and harms from physical activity?

  2011cites this paper
• Forty years later and the role of plasminogen activator inhibitor type 2/SERPINB2 is still an enigma.

  2011cites this paper
• Forty Years Later and the Role of Plasminogen Activator Inhibitor Type 2/SERPINB2 Is Still an Enigma

  2011cites this paper
• Plasminogen activator inhibitor type 2: still an enigmatic serpin but a model for gene regulation.

  2011cites this paper